Natural killer cell engager immunotherapeutic - Merck
Alternative Names: Second TriNKET™ immunotherapy candidateLatest Information Update: 15 Dec 2021
At a glance
- Originator Dragonfly Therapeutics
- Developer Merck & Co
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours